Thong Nhat JSC
Thong Nhat JSC operates in the real estate rental, development, and operations sector, generating revenue primarily through property development and management activities.
Business. Thong Nhat JSC (BAX.HN) is a real estate company engaged in rental, development, and operations activities. The firm generates revenue primarily through rental income within the Real Estate sector. Specific details regarding operating segments, headquarters location, and primary exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.
Analyst recommendations
17 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (confirmed · filed)2026-09-09
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressLisa McClain — Baxter International Inc. Common2025-10-31 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Baxter International Inc. Common2025-10-30 · Republican · MI · Purchase · $1,001 - $15,000
- CongressLisa McClain — Baxter International Inc. Common2025-10-30 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Baxter International Inc. Common2025-09-25 · Republican · MI · Purchase · $1,001 - $15,000
- CongressLisa McClain — Baxter International Inc. Common2025-08-04 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Baxter International Inc. Common2025-07-22 · Republican · MI · Purchase · $1,001 - $15,000
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Thong Nhat JSC (BAX.HN) is a real estate company engaged in rental, development, and operations activities. The firm generates revenue primarily through rental income within the Real Estate sector. Specific details regarding operating segments, headquarters location, and primary exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.
Thong Nhat JSC maintains a strong liquidity position, with a current ratio of 7.43, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to VND 22.8 billion, contributing to its robust liquidity profile. The absence of long-term debt further enhances its financial flexibility, as reflected in a debt-to-equity ratio of 0.
In terms of profitability, the company's return on equity (ROE) is 4.02%, and its return on assets (ROA) is 1.22%. These figures suggest that the company is generating modest returns relative to its equity and total assets. While the ROE is in line with the industry's typical performance, the ROA is relatively low, indicating that the company may not be efficiently utilizing its assets to generate profit.
The company's revenue is concentrated in a single business segment, as no specific segments are disclosed. Geographically, the company's exposure is primarily within Vietnam, with no significant international operations reported. This concentration may pose a risk if the domestic real estate market experiences a downturn.
Thong Nhat JSC's growth trajectory is supported by its operating income of VND 11.06 billion and net income of VND 8.83 billion. The company's capital expenditures were negative at VND -6.24 billion, suggesting a reduction in investment in new projects or assets. This could indicate a strategic shift or a response to market conditions.
The company's risk assessment indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags, and the absence of long-term debt reduces the likelihood of financial distress. The dilution potential is also low, with no significant changes in shares outstanding between basic and diluted figures.
Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's operating cash flow of VND 22.41 billion and free cash flow of VND 3.72 billion suggest a healthy cash generation capability, supporting its current operations and potential for future growth.
- Thong Nhat JSC has a strong liquidity position with a current ratio of 7.43 and no long-term debt.
- The company's ROE of 4.02% is modest, and its ROA of 1.22% indicates inefficient asset utilization.
- Revenue and operations are concentrated in a single segment and domestic market, posing concentration risk.
- The company's capital expenditures were negative, suggesting a strategic shift or reduced investment.
- Low liquidity and dilution risks are supported by strong cash flow and no immediate filing-based flags.
Bull / Bear case
Generated · model-assistedOperating and net margins significantly exceed the real estate cohort median, indicating superior profitability relative to peers.
The company maintains zero long-term debt, providing a strong balance sheet with no leverage risk compared to peers.
Revenue grew 51% year-over-year in the latest period, demonstrating strong top-line momentum despite historical volatility.
Free cash flow turned positive in the latest period, reversing a multi-year trend of negative cash generation.
Return on equity exceeds the cohort median, suggesting efficient use of shareholder capital despite low absolute levels.
Revenue and net income declined over the four-year CAGR period, indicating a long-term downward trend in business scale.
Return on assets and return on invested capital are extremely low, signaling inefficient capital deployment relative to book value.
Capital expenditure as a percentage of revenue is in the bottom quartile, potentially limiting future growth capacity.
Free cash flow was negative for four of the last five periods, highlighting inconsistent cash generation capabilities.
The latest revenue figure remains significantly below the peak recorded in FY-4, suggesting the business has not fully recovered.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Executive Vice President, CHRO · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 43 103 @ $20,37grant · 2026-02-27
- EVP and General Counsel · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 64 655 @ $20,37grant · 2026-02-27
- EVP and CFO · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 103 448 @ $20,37grant · 2026-02-27
- Director, President and CEO · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 488 506 @ $20,37grant · 2026-02-27
- Group Pres., ITT & Pharma. · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 57 471 @ $20,37grant · 2026-02-27
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Thong Nhat JSC Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,53 %$962M
- Investment Managers · as of 2024-06-300,05 %$2 109M
- Institutional Investor · as of 2026-03-310,04 %$777M
- Funds · as of 2026-03-310,03 %$220M
- Institutional Investor · as of 2022-09-300,03 %$0M
- Investment Managers · as of 2026-03-310,02 %$100M
- Investment Managers · as of 2025-12-310,02 %$1 197M
- Investment Managers · as of 2026-03-310,01 %$231M
- Investment Managers · as of 2026-03-310,01 %$94M
- Investment Managers · as of 2026-03-310,01 %$73M
- Investment Managers · as of 2026-03-310,01 %$336M
- Institutional Investor · as of 2026-03-310,01 %$24M
- Brokerage Firms · as of 2026-03-310,01 %$33M
- Investment Managers · as of 2026-03-310,01 %$73M
- Investment Managers · as of 2024-12-310,01 %$30M
- Investment Managers · as of 2026-03-310,01 %$65M
- Institutional Investor · as of 2026-03-310,01 %$44M
- Investment Managers · as of 2026-03-310,01 %$123M
- Investment Managers · as of 2026-03-310,01 %$10M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$5M
- Brokerage Firms · as of 2026-03-310,00 %$15M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- President, Adv. Surgery · Common Stock, $1 par valueOther 153 @ $18,68$3K · 2026-06-02
- President, CCS · Common Stock, $1 par valueOther 321 @ $18,68$6K · 2026-06-02
- SVP, Interim CFO, CAO & Cntrlr · Common Stock, $1 par valueOther 13 426 · 2026-06-01
- Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
- Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
- Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
- Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
- Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
- Director, Chair of the Board · Common Stock, $1 par valueOther 12 836 · 2026-05-05
- Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
- Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
- EVP and CFO · Common Stock, $1 par valueOther 8 153 @ $17,69$144K · 2026-03-06
- EVP and General Counsel · Common Stock, $1 par valueOther 6 620 @ $17,69$117K · 2026-03-06
- Group Pres., ITT & Pharma. · Common Stock, $1 par valueOther 2 848 @ $17,69$50K · 2026-03-06
- SVP, CAO and Controller · Common Stock, $1 par valueOther 1 932 @ $17,69$34K · 2026-03-06
- EVP,Group Pres,Healthcare · Common Stock, $1 par valueOther 12 674 @ $17,69$224K · 2026-03-06
- EVP and General Counsel · Common Stock, $1 par valueOther 1 336 @ $19,69$26K · 2026-03-02
- EVP,Group Pres,Healthcare · Common Stock, $1 par valueOther 1 614 @ $19,69$32K · 2026-03-02
- Group Pres., ITT & Pharma. · Common Stock, $1 par valueOther 1 852 @ $19,69$36K · 2026-03-02
- EVP and CFO · Common Stock, $1 par valueOther 42 735 · 2026-02-27
- Executive Vice President, CHRO · Common Stock, $1 par valueOther 17 806 · 2026-02-27
- Director, President and CEO · Common Stock, $1 par valueOther 201 804 · 2026-02-27
- Executive Vice President, CHRO · Common Stock, $1 par valueOther 11 871 · 2026-02-27
- EVP and General Counsel · Common Stock, $1 par valueOther 26 709 · 2026-02-27
- Group Pres., ITT & Pharma. · Common Stock, $1 par valueOther 23 742 · 2026-02-27
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -12.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -47.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -25.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -12.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 11.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -17.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 2.28xDerived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -47.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -22.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.31xDerived (calculated)
- Return on assets (FY 2025-12-31): -4.8%Derived (calculated)
- Return on equity (FY 2025-12-31): -15.6%Derived (calculated)
- Gross margin (FY 2025-12-31): 30.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -2,300.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -47.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
- Net margin (FY 2025-12-31): -8.5%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -28.4%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -15.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
- Operating cash flow (annual): USD 845MSEC XBRL filing
- R&D expense (annual): USD 518MSEC XBRL filing
- Gross profit (annual): USD 3.38BSEC XBRL filing
- Pre-tax income (annual): USD -505MSEC XBRL filing